Bicocca Open Archive

Logo unimib boa
CIACCIO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.621
EU - Europa 3.409
AS - Asia 3.389
SA - Sud America 595
Continente sconosciuto - Info sul continente non disponibili 379
AF - Africa 124
OC - Oceania 15
Totale 15.532
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.164
SG - Singapore 1.235
IT - Italia 918
CN - Cina 767
DE - Germania 510
RU - Federazione Russa 456
BR - Brasile 428
CA - Canada 397
HK - Hong Kong 389
VN - Vietnam 384
SE - Svezia 362
IE - Irlanda 271
GB - Regno Unito 200
UA - Ucraina 190
IN - India 156
FR - Francia 130
BD - Bangladesh 91
FI - Finlandia 75
AT - Austria 61
DK - Danimarca 58
AR - Argentina 53
TR - Turchia 51
IQ - Iraq 41
ZA - Sudafrica 36
ES - Italia 35
MX - Messico 35
NL - Olanda 34
PL - Polonia 32
EC - Ecuador 29
JP - Giappone 29
CO - Colombia 28
KR - Corea 28
SA - Arabia Saudita 28
BE - Belgio 25
VE - Venezuela 25
ID - Indonesia 24
PH - Filippine 21
PK - Pakistan 21
DZ - Algeria 16
ET - Etiopia 16
MA - Marocco 14
MY - Malesia 14
UZ - Uzbekistan 14
JO - Giordania 12
TW - Taiwan 11
AU - Australia 10
EU - Europa 10
IR - Iran 10
AE - Emirati Arabi Uniti 8
CZ - Repubblica Ceca 8
JM - Giamaica 8
KE - Kenya 8
OM - Oman 8
PY - Paraguay 8
AZ - Azerbaigian 7
CL - Cile 7
EG - Egitto 7
PE - Perù 7
TN - Tunisia 7
IL - Israele 6
NP - Nepal 6
BG - Bulgaria 5
CH - Svizzera 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
GA - Gabon 4
HU - Ungheria 4
LT - Lituania 4
MD - Moldavia 4
MM - Myanmar 4
RS - Serbia 4
BH - Bahrain 3
BO - Bolivia 3
CR - Costa Rica 3
GR - Grecia 3
LB - Libano 3
MN - Mongolia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
RO - Romania 3
BB - Barbados 2
DO - Repubblica Dominicana 2
HR - Croazia 2
KG - Kirghizistan 2
KW - Kuwait 2
LY - Libia 2
NC - Nuova Caledonia 2
SC - Seychelles 2
SN - Senegal 2
SR - Suriname 2
ZM - Zambia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BF - Burkina Faso 1
BT - Bhutan 1
BW - Botswana 1
BY - Bielorussia 1
Totale 15.147
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.025
Singapore 754
Ashburn 667
San Jose 514
Woodbridge 448
Hong Kong 384
Fairfield 350
Houston 317
Chandler 311
Frankfurt am Main 292
Toronto 280
Dublin 262
Milan 244
Wilmington 219
New York 205
Jacksonville 181
Dearborn 154
Council Bluffs 143
Los Angeles 136
Seattle 133
Cambridge 127
Santa Clara 126
Dallas 120
Beijing 119
Princeton 104
Ho Chi Minh City 95
Hanoi 94
Chicago 92
The Dalles 88
Rome 74
Nanjing 66
Shanghai 61
Buffalo 54
Vienna 54
Altamura 53
Lauterbourg 48
Columbus 47
Lawrence 47
São Paulo 44
Helsinki 37
Moscow 37
Hefei 32
Orem 32
Lachine 31
Dong Ket 26
San Diego 26
Guangzhou 25
Lissone 25
Warsaw 25
Boardman 24
London 23
Tokyo 23
Boston 22
Shenyang 22
Da Nang 21
Denver 21
Haiphong 21
Brooklyn 20
Phoenix 20
Montreal 19
Munich 19
Nanchang 19
Johannesburg 18
Ottawa 18
Brussels 17
Manchester 17
Pune 17
Tianjin 17
Baghdad 16
Bologna 16
Fremont 16
Andover 15
Atlanta 15
Changsha 15
Rio de Janeiro 15
Seoul 15
Washington 15
Chennai 14
Mexico City 14
Mumbai 14
Brasília 13
Dhaka 13
Jakarta 13
Jiaxing 13
Philadelphia 13
San Francisco 13
Jinan 12
Nuremberg 12
Poplar 12
Tashkent 12
Zhengzhou 12
Kuala Lumpur 11
Sacramento 11
Hebei 10
Istanbul 10
Jeddah 10
Naples 10
Nürnberg 10
Paris 10
Riyadh 10
Totale 9.616
Salva come PNG Salva come JPEG
Nome #
Impact of multidisciplinary team approach to liver tumors: 5-Years experience 534
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 505
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 474
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 400
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 372
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 353
Health related quality of life in chronic liver diseases 347
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 345
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 345
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 337
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 331
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 329
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 326
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 320
The impact of liver disease on the health-related quality of life 319
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 313
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 311
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 303
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 301
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 300
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 300
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 299
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 298
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 292
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 292
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 287
Difference in health related quality of life of chronic liver diseases and general population 285
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 284
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 283
Health Related Quality of Life in the Major Liver Conditions 281
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 276
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 267
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 262
Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era 260
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 258
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 258
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 256
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 254
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 249
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 240
Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: A systematic review and meta-analysis 239
Functional liver imaging score (FLIS) can predict adverse events in HCC patients 237
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 229
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 229
Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1 229
Management of Chronic hepatitis C (CHC) Genotype 1 treatment-naive patients in an era of rising opportunities and costs - A cost-effectiveness analysis of treatment options 223
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 212
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 204
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 197
Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? 194
Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis 186
Sofosbuvir and ribavirinin in HCV-infected patients listed for liver transplantation: A cost-effectiveness analysis 184
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 172
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 151
Totale 15.532
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022614 0 0 87 85 32 57 13 53 37 65 49 136
2022/20231.344 144 446 121 111 82 170 31 82 97 9 38 13
2023/2024856 30 33 22 68 86 262 158 37 61 12 8 79
2024/20252.021 108 210 146 83 172 91 134 71 234 347 148 277
2025/20265.433 630 217 396 558 619 285 746 205 419 534 462 362
2026/2027554 139 212 203 0 0 0 0 0 0 0 0 0
Totale 15.532